Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3551854 | 0.87 | TDP1 (0.43) | ATML3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL3739665 | 0.82 | ATM (0.48) | ATML3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL1578576 | 0.82 | ATM (0.48) | ATML3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL4684014 | 0.82 | L3MBTL1 (0.60) | ATML3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL6043558 | 0.80 | ATM (0.77) | ATML3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL7506937 | 0.80 | L3MBTL1 (0.69) | ATML3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL1578993 | 0.80 | ATM (0.47) | ATML3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL3736530 | 0.79 | NPC1 (0.47) | ATML3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL7514173 | 0.79 | ATM (0.45) | ATML3MBTL1NPC1MEN1KMT2A | |
| SCHEMBL7510577 | 0.79 | ATM (0.45) | ATML3MBTL1NPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655652-B2 | 2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine hydrochloride; cell cycle inhibitory; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| US-20070161615-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| EP-1748999-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005075461-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
| EP-0858996-B1 | NERVE CELL PROTECTIVE AGENTS | MOCHIDA PHARM CO LTD (JP) | 2004-10-27 | — | — | EP | disclosed |
| US-6040331-A | Nerve cell protective agents | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-03-21 | — | — | US | disclosed |
| EP-0858996-A1 | NERVE CELL PROTECTIVE AGENTS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1998-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161615-A1 | Chemical compounds | MKI67, PCNA, CCNI | ATM 2811/4885L3MBTL1 3296/4885NPC1 3075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.